De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Noxopharm Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Gisela Mautner

Algemeen directeur

AU$491.6k

Totale compensatie

Percentage CEO-salaris	83.4%
Dienstverband CEO	2.5yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Gisela Mautner's beloning veranderd ten opzichte van Noxopharm's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	n/a	n/a	-AU$12m
Sep 30 2023	n/a	n/a	-AU$14m
Jun 30 2023	AU$492k	AU$410k	-AU$15m
Mar 31 2023	n/a	n/a	-AU$15m
Dec 31 2022	n/a	n/a	-AU$15m
Sep 30 2022	n/a	n/a	-AU$17m
Jun 30 2022	AU$1m	AU$201k	-AU$19m

Compensatie versus markt: De totale vergoeding ($USD 323.65K ) Gisela } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Gisela is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Gisela Mautner

2.5yrs

Tenure

AU$491,562

Compensatie

Dr. Gisela Mautner is Non-Executive Director of Nyrada Inc. from August 1, 2022. She serves as Director at Noxopharm Limited. She served as Chief Medical Officer at Noxopharm Limited since October 2019 unt...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gisela Mautner	CEO, Executive MD & Director	2.5yrs	AU$491.56k	geen gegevens
Shawn Van Boheemen	Chief Financial Officer	5.3yrs	geen gegevens	geen gegevens
Jeanette Bell	Chief Operating Officer	4.6yrs	geen gegevens	geen gegevens
John Wilkinson	Chief Scientific Officer of Oncology	2.6yrs	geen gegevens	geen gegevens
Olivier Laczka	Chief Scientific Officer of Inflammation	2.6yrs	geen gegevens	geen gegevens
David Franks	Company Secretary	7.6yrs	AU$16.49k	geen gegevens

3.6yrs

Gemiddelde duur

Ervaren management: Het managementteam van NOXO.F wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gisela Mautner	CEO, Executive MD & Director	no data	AU$491.56k	geen gegevens
Frederick Bart	Non-Executive Chairman	4.3yrs	AU$45.00k	2.57% A$ 375.7k
Peter Marks	Non-Executive Deputy Chairman	8.4yrs	AU$60.00k	0.31% A$ 45.0k
Boris Patkin	Non-Executive Director	4.4yrs	AU$56.69k	0.22% A$ 31.5k

4.4yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NOXO.F wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Noxopharm Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Recent updates

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial

Noxopharm Limited Announces Award of Federal Innovation Connections Grant

Noxopharm Limited Announces CEP-2 Safety Milestone Shows Veyonda Progress

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Noxopharm Limited Reviews the Safety Data from the First Cohort of Patients in the Trial

Noxopharm Limited Announces DARRT-2 Trial Safety Milestone and European Site Activated

Noxopharm Limited Announces Mayo Clinic and Washington University Join Its Sarcoma Trial

Veyonda Abstract Published at ASCO Annual Meeting 2022

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Noxopharm Limited Announces Phase 1 CEP-2 Sarcoma Trial is Underway with a First Patient Enrolled and Dosed At City of Hope in Los Angeles, California

Noxopharm Limited Announces First Patient Dosed in CEP-2 Sarcoma Trial at the US City of Hope Cancer Center

Noxopharm Limited Announces Veyonda Achieves Important U.S. Patent Claims

Noxopharm Announces Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Noxopharm Limited Releases Preliminary Top Line Data of Its NOXCOVID Phase 1 Clinical Trial

Noxopharm Limited's DARRT-2 Study Receives IND Approval from FDA

Noxopharm Limited Updates the Market on Progress with its DARRT-2 Trial

Noxopharm Limited Announces the Release of Clinical Data Relating to the Experimental Radioligand

Noxopharm Limited Announces New Independent Trial Data Supports Potential of Veyonda as Major New Anti-Cancer Drug

Noxopharm Limited’s Veyonda to Begin First-Line Sarcoma Treatment Testing

Oxopharm Limited Announces That Its Cep-2 Study Will Open Shortly

Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm

Noxopharm IONIC Immuno-Oncology Trial Commences

Noxopharm Limited Announces Veyonda Approved to Move into Second and Final Stage of the NOXCOVID-1 Clinical Trial on the Advice of the Clinicians Treating the NOXCOVID-1 Patients

Noxopharm Limited Provides More Detailed Summary of Data from the Lupin Study That Formally Presented to the American Society of Clinical Oncology Genitourinary Cancers Symposium

Noxopharm Limited Reports the Publication in Abstract Form of the Latest Survival Data from the LuPIN Study

Noxopharm Limited Announces the Latest Formal Review by the NOXCOVID-1 Safety Steering Committee Cleared it to Advance to the Fifth and Final Dosage Cohort

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd